{"id":"W2606639948","doi":"10.5489/cuaj.4398","title":"First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience","year":2017,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre; Montreal General Hospital; BC Cancer Agency; University of Calgary; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Ottawa Hospital; CancerCare Manitoba; University Health Network; University of Toronto; University of Alberta; Queen Elizabeth II Health Sciences Centre; McGill University","funders":"","keywords":"Pazopanib; Sunitinib; Medicine; Hazard ratio; Renal cell carcinoma; Internal medicine; Oncology; Proportional hazards model; Confidence interval; Mucositis; Kidney cancer; Urology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001290286,0.000266712,0.0005190725,0.0005068982,0.001104942,0.000932736,0.0006863209,0.0003238941,0.001591011],"category_scores_gemma":[0.002928612,0.0001096783,0.0004691256,0.002413082,0.000560399,0.0003288158,0.0004785271,0.0007375252,0.0001482838],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02033965,"about_ca_system_score_gemma":0.02838967,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8661203,"about_ca_topic_score_gemma":0.9374482,"domain_scores_codex":[0.9989665,0.0001115468,0.00004270678,0.0001240027,0.0005744718,0.0001807232],"domain_scores_gemma":[0.9980696,0.0001909291,0.0003182357,0.00006559121,0.0007038705,0.0006517746],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002967573,0.0005532206,0.5308435,0.001755088,0.0006446811,0.001392503,0.001480851,0.001630689,0.001910889,0.001834853,0.03030758,0.4246785],"study_design_scores_gemma":[0.0009824187,0.001625717,0.8915553,0.0007852238,0.0007597604,0.004893783,0.00124135,0.001201926,0.001613968,0.0003300057,0.09492468,0.00008591126],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8421809,0.1208147,0.0006186075,0.007769573,0.0002522552,0.0001552424,0.003280739,0.00005636991,0.02487151],"genre_scores_gemma":[0.9492446,0.04544014,0.0006492722,0.001081388,0.0001516015,0.00002650577,0.00187809,0.00001840935,0.001509991],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1338797,"threshold_uncertainty_score":0.2693363,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05555852489601952,"score_gpt":0.276163788417907,"score_spread":0.2206052635218875,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}